Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits
Ono Pharmaceutical suffered a 4.7% sales decline for its flagship PD-1 inhibitor Opdivo (nivolumab) in April-December as its label expansions failed to counter its 37.5% price cut in November 2018 and ever-intensifying competition on the market. Despite the fall, the…
To read the full story
Related Article
- Ono’s FY2019 Sales Up 1.3% on Keytruda-Tied Royalties
May 13, 2020
- Ono Checks In 3.2% Revenue Growth on Opdivo, Forxiga in 1st Half
November 1, 2019
- Ono’s Drug Sales Skid in Q1, but Opdivo Royalties Underpin Earnings
August 2, 2019
BUSINESS
- Medii, Pediatric Neurology Society Build System to Support Elevidys Use
April 24, 2026
- Oncolys’ OBP-301 Wins US Fast Track Designation
April 24, 2026
- Rituxan Biosimilar Expands Nephrotic Syndrome Indication in Japan
April 24, 2026
- Gilead Files Trodelvy-Keytruda Combo for 1L TNBC in Japan
April 24, 2026
- Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…